Kornimate/medical-research-clean huggingface dataset:
double-layer versus purse uterine closure techniques : impact on residual myometrial thickness after cesarean

Conditions: Uterine Scar Defect

Summary: there are different surgical techniques of uterine closure during cesarean. currently data suggest that the double layer unlocked closure technique is associated with better uterine scar healing, and this technique is considered the gold standard. this study compares two techniques of uterine closure on myometrium thickness: 1. double layer unlocked suture; 2. purse suture of the uterus with a first continuous purse suture of the deep portion of the myometrium and a second unlocked continuous suture including the remaining part of the myometrium. the primary outcome is the mean residual myometrium thickness at the site of the uterine scar evaluated by transvaginal ultrasound at six months after cesarean.


Eligibility criteria:
inclusion criteria: * planned cesarean * primary cesarean * ≥ 38 gestational weeks exclusion criteria: * previous cesarean * women \< 18 years old * multiple gestation * mullerian anomalies * active labor * diabetes * bmi \>35 kg/m2 * placenta praevia * chronic systemic disease * covid-19 infection

Keywords: niche
subgroups of older adults with back pain and multiple chronic conditions

Conditions: Low Back Pain; Depression; Anxiety; Osteoarthritis

Summary: the overall goal of this study is to use the national health and aging trends study (nhats) data to gain an understanding of how multiple chronic conditions impact the health outcomes of older adults with back pain.

this study seeks to gain knowledge regarding how multiple chronic conditions affect the health and function of older adults with back pain. the investigators will perform a retrospective cohort study using secondary analysis of the national health and aging trends study (nhats) data. nhats collected longitudinal data on medicare beneficiaries over 65 for six years, from 2011-2017. this set of data is comprehensive and includes self-reported survey data as well as physical performance data, both of which this study will utilize. the specific aims include to 1) estimate the longitudinal associations of the number of chronic conditions, using a standard classification scheme, with long-term physical performance, function, and recurrent falls, 2) identify specific combinations of chronic conditions that are most strongly associated with long-term physical performance, function, and recurrent falls, 3) determine the association of the number and type of chronic conditions with rehabilitation service use. the investigator will test a corresponding hypothesis for each aim: 1) medicare beneficiaries reporting back pain with a greater number of chronic conditions will have worse physical performance, lower functional status, and be more likely to experience recurrent falls over 6 years, 2) medicare beneficiaries reporting back pain with common and potentially modifiable conditions of anxiety, depression, and arthritis (individually and combined as dyads or a triad) will have worse physical performance, lower functional capacity, and be more likely to experience recurrent falls over 6 years, 3) medicare beneficiaries with back pain and multiple chronic conditions will report lower use of rehabilitation services in the past one year compared to those with back pain alone or one additional chronic condition.

Eligibility criteria:
inclusion criteria: * this study will include community-dwelling participants in the nhats study who indicated that in the last month they had been bothered by pain in the last month and indicated that the site of pain was the lower back. exclusion criteria: * this study will exclude participants who are non-ambulatory (requires wheelchair or scooter).

Keywords: comorbidity pain function older adults medicare
clinical profile in patients with essential tremors

Conditions: Essential Tremor

Summary: essential tremors are no longer a single motor disorder but disorder of movement associated with non-motor symptoms and the aim of this study is to explore the clinical profile of patients with essential tremors including motor and non-motor features and their relationship. and to identify clinical predictors of these features.

essential tremors (et) was defined as mono-symptomatic tremor syndrome involving both upper limbs during action for at least 3 years, with or without tremor in other body parts . et is considered the most prevalent adult movement disorder, the crude prevalence of et varies widely from 0.08 to 220 cases per 1000 persons. many pathological post-mortem studies are providing evidence that et is mostly can be recognizes as neurodegenerative disease of the cerebellum and brain stem . in the last decade there is an emerging studies that discuss the presence of associated motor, non- motor, sensory and psychological symptoms besides the tremors . motor features of et are not confined to tremors. another feature of et is gait ataxia , eye movement abnormalities of subclinical degree, difficulties in learning motor skills, bradykinesia and slowness of finger tapping . studies of the last two decades reported mild cognitive deficits in patients with et in comparison to healthy controls. these deficits affect number of cognitive domains, especially verbal memory, naming, verbal fluency, attention- concentration, working memory and concept formation . in addition et was found to be associated with hearing impairment with abnormal threshold at higher tone frequencies which refer to sensorineural hearing loss, and olfactory deficits which both may points to cochlear pathology. moreover, patients with et thought to have higher incidence of depression and anxiety symptoms than age-matched healthy individuals correlated with tremors severity .

Eligibility criteria:
inclusion criteria: 1. all adults patients are fulfilling cases definition of essential tremors will be included. 2. gender: both sexes are included. 3. any patient is, able to provide informed consent including permission to obtain information from patients' clinical medical history of at least three years' duration exclusion criteria: 1. patients are diagnosed with other neurological disorders unrelated to essential tremors. 2. patients had any other condition presented with other cognitive or psychiatric disorders or known as drug abusers. 3. patient had any systemic disease presented with tremors rather than essential tremors or compliant on medication had tremors side effect.
safety and efficacy of prulifloxacin vs placebo in treatment of acute gastroenteritis in adult travelers

Conditions: Acute Bacterial Gastroenteritis

Summary: the objective of this pivotal phase iii study is to investigate the safety and efficacy of prulifloxacin versus placebo in the treatment of patients with acute bacterial gastroenteritis (traveler's diarrhea.

this double-blind trial will compare the safety and efficacy of prulifloxacin versus placebo in adult travelers with acute gastroenteritis characterized by diarrhea with one or more of the following signs or symptoms: nausea, vomiting, abdominal pain or cramping, fecal urgency, moderate to severe other gastrointestinal-related symptoms, or tenesmus of \<72 hours duration.

Eligibility criteria:
inclusion criteria: * diagnosis of acute bacterial gastroenteritis * traveler from an industrialized country * capable of giving informed consent exclusion criteria: * fever (\>100.3 degrees) * pregnant or breast feeding or not using adequate birth control * known or suspected (co-)infection with non-bacterial pathogen * symptoms of acute gastroenteritis of \>72 hours duration * bloody diarrhea * concomitant antibacterial with activity against enteric bacterial pathogens * history of ibd * unable/unwilling to comply with study protocol * greater than two doses of an antidiarrheal medication within 24 hours * \> 2 doses of anti-diarrheal medication within 24 hours * antimicrobial treatment within 30 days

Keywords: traveler's diarrhea
re-search study: a study to learn how and in which amount regorafenib is given in usual practice to patients in spain: a study looking back at cases that have already happened when the study begins.

Conditions: Metastatic Colorectal Cancer

Summary: researchers are collecting more information to improve treatment of metastatic colorectal cancer (mcrc) with regorafenib. metastatic colorectal cancer (mcrc) is a cancer that starts in the large bowel and involves the rectum (the lowest part of the gut) and has spread to other parts of the body. regorafenib is available to treat patients with mcrc that have previously been treated with, or are not considered candidates for, available therapies. it is an anti-cancer drug that blocks several proteins called enzymes which are involved in the growth of cancer. it is known that doctors may change the amount (the dose) of regorafenib they give, so that the patients better tolerate the treatment. little information is however available on the doses of regorafenib given in spain in usual practice. in this study researchers want to learn how and in which amount regorafenib is usually given to patients with mcrc in spain. they aim to identify the starting dose of regorafenib and to describe dosing patterns during the first two four-week treatment periods (cycles) according to usual clinical practice. to answer these questions, the researchers will look back at cases that have already happened when the study begins. medical history data from the day of diagnosis of the mcrc until the day prior to the inclusion in the study is collected from the medical records of adult patients with mcrc. all patients must have started their treatment with regorafenib since january 2017 and have taken regorafenib for at least 3 months. the researchers will collect the information between around june 2021 until around november 2021. the final report is planned to be available in july 2022. no investigational products will be administered in this study. moreover, no additional visits or laboratory tests will be performed apart from the usual tests/treatments done in usual practice.


Eligibility criteria:
inclusion criteria: * patient ≥ 18 years * patients with histological confirmation of mcrc * patient who started treatment with regorafenib for mcrc according to usual clinical practice during or after january 2017 and at least 3 months prior to the inclusion in the study exclusion criteria: * patient who have been treated with regorafenib during their participation in a clinical trial

Keywords: colorectal cancer refractory metastatic colorectal cancer observational study regorafenib
chlorhexidine mouthrinse before ebus-tbna

Conditions: Endobronchial Ultrasound

Summary: the purpose of this study is to investigate whether chlorhexidine mouthrinse is effective in preventing microbial contamination during endobronchial ultrasound-guided transbronchial needle aspiration (ebus-tbna).

ebus-tbna using the convex probe is a standard of care for the assessment of mediastinal and hilar lymphadenopathy. although ebus-tbna is a minimally invasive procedure, rare but serious infectious complications such as pneumonia, lung abscess, empyema, mediastinal adenitis/abscess, mediastinitis, pericarditis, and sepsis were reported. ebus-scope might be contaminated with oropharyngeal commensal bacteria while passing the oropharyngeal airway during ebus-tbna. contamination of punctured lymph nodes by oropharyngeal commensal bacteria can cause severe infections. chlorhexidine gluconate is an antimicrobial agent that has a broad antibacterial activity including both gram-positive and negative bacteria. chlorhexidine has been widely used for surgical scrub, skin disinfection, and mouthrinse. we, therefore, designed a phase 4, single-center, randomized, controlled clinical trial to investigate whether chlorhexidine mouthrinse is effective in preventing microbial contamination during ebus-tbna.

Eligibility criteria:
inclusion criteria: * inpatients aged 19 years and older who are scheduled to undergo ebus-tbna using a convex probe exclusion criteria: * antiseptic mouthrinse within 7 days before inclusion; * active infection or antibiotic treatment within 7 days before inclusion; * immunocompromised; * trachemostomy status; * who have already undergone gastroscopy on the same day when ebus- tbna is scheduled to be administered

Keywords: endobronchial ultrasound transbronchial needle aspiration chlorhexidine infection complication
are ems personnel prepared to identify and decompression of tension pneumothorax

Conditions: Tension Pneumothorax

Summary: the study aims to determine the level of knowledge and skills to recognize and decompression of tension pneumothorax


Eligibility criteria:
inclusion criteria: * give voluntary consent to participate in the study * maximum 1 year of work experience in medicine * paramedics, nurses, physicians exclusion criteria: * not meet the above criteria * wrist or low back diseases * pregnancy
"ventricular tachycardia ablation registry".

Conditions: Ventricular Tachycardia

Summary: catheter ablation of ventricular tachycardias is a well-established approach in clinical practice in patients with implantable cardioverter defibrillator (icd) implanted. previous studies have shown a significant reduction in appropriate shocks (\~ 20%) and a significant reduction in hospitalizations for cardiovascular reasons (\~ 12%) in patients with ischemic heart disease treated with ablation. recent works have also shown the effectiveness of the ablation procedure using as procedural target the reduction of late potentials. however, actually it is necessary to have an homogenize and accepted mapping scheme in sinus rhythm to ablate ventricular tachycardias related to scar substrate in patients with: * previous mi * previous myocarditis * arrhythmogenic right ventricular dysplasia (arvd) * idiopathic dilated cardiomyopathy (idcm) scope of the registry is to collect data during cardiac mapping in sinus rhythm in patients indicated for ventricular tachycardia ablation, that will be performed per clinical practice, by using the st. jude medical ensitetm precisiontm mapping system. the objective of the present registry is: to assess the acute and long-term efficacy of the strategy of substrate abolition (abolishment of complex and late potentials) guided by electroanatomic mapping with precision software.

this is an italian multicenter, observational, prospective and retrospective registry. data will be collected during enrollment/baseline, procedure, pre-discharge and during the follow-up visits according to the standard practice of participating centers, with mandatory visits at 6 and 12 months. data can also be collected retrospectively, prior informed consent of the patient. the planned enrollment duration is approximately 24 months.

Eligibility criteria:
inclusion criteria: * patients with an implanted icd * patients with indication to ventricular tachycardia ablation procedure, supported by ensite precision 3d mapping system (previous mi, myocarditis, arvd, idcm) * age 18 years or more * able to provide an informed consent to participate to the registry and available to respect the assessments described in the protocol exclusion criteria: * contraindication to anticoagulants * presence of thrombi * presence of mitral and aortic prosthetic valve * recent (\<3 months) myocardial infarction or unstable angina or coronary artery bypass * pregnant or nursing * ventricular tachycardia caused by reversible pathology * \< 1 year life expectancy according to the investigator * contraindication to the use of ablation/diagnostic catheters or to cardiac catheterism
anti-oxidant effect on peritoneal membrane in peritoneal dialysis (pd) patients

Conditions: End-Stage Kidney Disease; Peritoneal Dialysis

Summary: peritoneal fibrosis is one of the major causes of technical failure in patients on peritoneal dialysis (pd) for long period of time. although the exact mechanisms of peritoneal damage during pd still remain unclear, generation of reactive oxygen species may be responsible for progressive membrane dysfunction. n-acetylcysteine (nac)is a powerful antioxidant shown to protect peritoneal fibrosis in peritoneal dialysis animal model. in this study the researchers investigated the hypothesis that nac protect peritoneal membrane damage.

n-acetylcysteine (nac) is known to be relatively safe and beneficial in peritoneal dialysis patient at a dose of 1200 mg per day. patients will be randomly assigned to nac and control group and prescribed according to the protocol. at 2 and 6 month, peritoneal equilibrium test (pet) will be performed with blood sampling.

Eligibility criteria:
inclusion criteria: * maintenance peritoneal dialysis at least 3 months * patients who are able and willing to understand, sign and date an informed consent document, and authorize access to protected health information exclusion criteria: * episode of peritonitis at least 3 months * episodes of admission due to other disease at lease 3 months * liver disease * allergic history with n-acetylcysteine

Keywords: antioxidant epithelial to mesenchymal transition peritoneal fibrosis peritoneal dialysis, continuous ambulatory
neoadjuvant folfoxiri versus capeox chemotherapy for local advanced rectal cancer

Conditions: Rectal Cancer

Summary: this is a phase iii randomized controlled trial comparing the efficacy and safety of folfoxiri versus capeox as neoadjuvant regimen in treating patients with middle and upper locally advanced (mri t3-4 or n+) rectal cancer. this study aims to optimize the neoadjuvant therapy for patients with anus-preserving resectable locally advanced rectal cancer, so as to improve the prognosis of them. it remains unclear about whether folfoxiri or capeox neoadjuvant chemotherapy is more effective for locally advanced rectal cancer.


Eligibility criteria:
inclusion criteria: * mri evaluated of t3-4 or n+ rectal cancer; * pathologically diagnosed of rectal adenocarcinoma; * 18 to 75 years old; * distance from lower margin of tumor to anus \<15 cm and suitable for anus-preserving resection; * tumor amenable to radical resection; * treatment-na?ve patients with no previous systemic chemotherapy, radiotherapy or local excision for treating rectal cancer; * laboratory requirements conducted within 7 days of starting study treatment: neutrophil count ≥ 1.5×10\^9/l, platelet count ≥ 100×10\^9 /l, hemoglobin ≥ 80 g/l, serum bilirubin ≤ 24umol/l, alanine aminotransferase and aspartate aminotransferase ≤ 60 u/l, serum creatinine ≤ 110 umol/l; * be capable to receive a surgery; * no second tumor at present or in the past 5 years, except skin basal cell carcinoma, skin squamous cell carcinoma, or any in situ cancer; * no previous systemic chemotherapy for treating colorectal cancer; * life expectancy of more than 3 months; * no current pregnancy or breast-feeding, and subjects at childbearing age shall take method of contraception; * eastern cooperative oncology group (ecog) performance status (ps) ≤ 1; * be willing and able to understand the study and to provide written informed consent. exclusion criteria: * end-stage cachexia patients; * cardiopulmonary dysfunction or liver and kidney dysfunction, and unable to tolerate chemotherapy or surgery; * metastatic carcinoma; * incomplete or complete intestinal obstruction; * known to be allergic to capecitabine, 5-fu, oxaliplatin or irinotecan; * pregnant or lactating women; or women who have fertility but have not taken at taken adequate contraceptive measures; * have vital organ failure or other severe diseases, including but not limited to coronary heart disease, cardiovascular diseases, or myocardial infarction within 12 months before being included; severe neurological or psychiatric historysevere infection; active disseminated intravascular coagulation; active hepatitis, severe coagulation disorder patients; * history of other malignancy within the past 5 years except effectively treated skin basal cell carcinoma, skin squamous cell carcinoma, or any in situ cancer; * serious organic disease including but not limited to heart, kidney, brain, and lung.

Keywords: neoadjuvant chemotherapy locally advanced rectal cancer folfoxiri capeox
aimigo 12l ecg synthesis software pivotal study for arrythmia detection

Conditions: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Bradycardia; Tachycardia

Summary: the study is a prospective single-arm multicenter clinical trial. adult patients will be consented and enrolled in an outpatient cardiology office or arrhythmia clinics.

the purpose of this study is to conduct clinical validation of the aimigo 12-lead synthesis software against a standard fda-cleared 12-lead ecg system, based on quantitative and qualitative assessment of paired recordings from the same patient, in sinus rhythm or during episodes of symptomatic non-life-threatening arrhythmia. the study will provide the necessary data for an fda 510(k) regulatory submission and develop experience for market access and integration into clinical workflows.

Eligibility criteria:
inclusion criteria: 1. male or female subjects over 18 years of age. 2. referred to outpatient arrhythmia clinic with a history of one or more of the following conditions: 1. previous diagnosis of arrhythmia presenting to the clinic for routine follow-up evaluation. 2. patients with symptoms indicative of cardiac arrhythmias. 3. able and willing to sign informed consent. exclusion criteria: 1. open chest wounds or recent (\<30 days) surgery to the chest or abdomen. 2. clinical conditions that in the opinion of the investigator would compromise the safety of the patient or ability to complete the protocol.

Keywords: telemedicine cardiac arrhythmia ecg synthesis software diagnostic vectorcardiography remote monitoring